Max Robotics — Global Service Robot Directory + US Certification

About

Yasuhide Kitagawa is a leading urological oncologist whose research focuses on prostate cancer epidemiology, treatment trends, and regional disparities in Asia. His major contributions center on large-scale, multi-institutional analyses that track how initial treatments for prostate cancer have evolved over time, particularly in Japan. In his landmark 2024 study, Kitagawa demonstrated a significant shift away from androgen deprivation therapy (ADT) as the primary treatment for newly diagnosed prostate cancer, reflecting the impact of modern surgical and radiation technologies. This work, already garnering 14 citations, provides critical insights for clinicians adapting to changing therapeutic landscapes. Kitagawa also played a pivotal role in the Asian Prostate Cancer (A-CaP) study, an ambitious Asia-wide initiative launched in 2015. His 2018 report from the third A-CaP meeting (12 citations) helped clarify distribution patterns of prostate cancer treatments across diverse Asian populations, highlighting the need for region-specific guidelines. Through these collaborative efforts, Kitagawa has shaped our understanding of how cultural, economic, and technological factors influence prostate cancer management, making his work essential reading for researchers and clinicians addressing cancer care disparities in Asia.